Both Democrat Hillary Clinton and Republican Donald Trump have reportedly tapped policy experts with some healthcare experience for their transition teams.
The FDA has granted tentative approval to a highly contested drug for muscular dystrophy that has become a flashpoint in the debate over patient access to experimental medicine.
The generic drug industry, responding to public anger over big price hikes for some generic products, is calling for action on a bipartisan Senate bill it says would increase the number of cheaper generic drugs and reduce U.S. drug spending.
In the three years since the FDA published final regulations on a unique device identifier system, most manufacturers and distributors have successfully started phasing in UDIs for their products. But few healthcare providers are able to take full advantage of the data.
The threat of infection from tainted medical instruments is growing as the devices become more complex and harder to clean.
The FDA issued a final rule Friday that essentially bans companies from being able to market antiseptic wash products that contain any of 19 active ingredients out of concerns long-term daily use could pose a number of health risks.
The government needs to better protect consumers from high prescription medication costs by setting tougher standards for companies seeking drug exclusivity protection for their brand name products, according to a study.
Michelle Obama during her nearly eight years in the White House succeeded in changing the national conversation about diet and exercise, and gave a major boost to transparency about the foods we eat.
Guardant Health, based in Redwood City, Calif., developed a liquid biopsy blood test that has helped match cancer patients with clinical trials and treatment options without costly or invasive biopsies. CEO and co-founder Helmy Eltoukhy calls it a “game changer” for oncology.
Federal authorities gave final approval Friday to a plan to release genetically modified mosquitoes in Florida, but none of the insects will be immediately dispatched in the state's fight against the spread of Zika.
Houston-based Decisio Health developed the first FDA-approved web-based clinical platform and created easy-to-read displays that alert clinicians to problems as they emerge.
History buffs and infectious-disease experts have already drawn links between the rubella outbreak in the 1960s and the current spread of Zika. But drugmakers today face greater regulatory hurdles, and the federal government has yet to dedicate funding to address the Zika epidemic.